ArticleMolecular biology reports2026
Effects of intracerebroventricular Metrnl administration on the hypothalamic-pituitary-testicular axis in male rats.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMetrnl (Meteorin-like) is a recently identified adipokine expressed in key components of the hypothalamic-pituitary-testicular (HPT) axis. However, its role in male reproductive function remains unclear. This study aimed to investigate the effects of central Metrnl administration on the HPT axis and spermatogenesis in male rats. METHODS AND
resultsForty adult male Wistar-Albino rats were randomly divided into four groups (n = 10 per group): control, sham, 10 nM Metrnl, and 100 nM Metrnl. Metrnl was administered via intracerebroventricular infusion for 14 days. Metrnl treatment significantly decreased hypothalamic GnRH mRNA and protein expression (p < 0.05). Accordingly, serum LH, FSH, and testosterone levels were significantly reduced in the treatment groups compared to controls (p < 0.05). Histological analysis revealed increased seminiferous tubule diameter and decreased germinal epithelial thickness (p < 0.05). Immunohistochemical evaluation demonstrated a dose-dependent reduction in HSD3B1 and vimentin immunoreactivity, more pronounced at 100 nM. Additionally, sperm concentration and motility were significantly decreased in both treatment groups (p < 0.05).
conclusionsCentral Metrnl administration suppresses the HPT axis at the hypothalamic level, leading to reduced gonadotropin and testosterone secretion. This suppression is associated with impaired Leydig and Sertoli cell function and diminished sperm quality. These findings identify Metrnl as a potential negative regulator of male reproductive function.
Indexed as
Identifiers
42118438What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.